mizagliflozin   Click here for help

GtoPdb Ligand ID: 9547

Synonyms: DSP-3235 | KWA 0711 | KWA-0711 | KWA0711
Compound class: Synthetic organic
Comment: Mizagliflozin is a novel orally bioavailable and selective sodium glucose co-transporter 1 (SGLT1) inhibitor. It acts locally in the intestinal lumen to block postprandial glucose absorption. It increases luminal water and is proposed to loosen stools [3,5].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 9
Hydrogen bond donors 7
Rotatable bonds 14
Topological polar surface area 192.41
Molecular weight 564.32
XLogP 1.53
No. Lipinski's rules broken 2

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES OCC1OC(Oc2n[nH]c(c2Cc2ccc(cc2C)OCCCNCC(C(=O)N)(C)C)C(C)C)C(C(C1O)O)O
Isomeric SMILES OC[C@H]1O[C@@H](Oc2n[nH]c(c2Cc2ccc(cc2C)OCCCNCC(C(=O)N)(C)C)C(C)C)[C@@H]([C@H]([C@@H]1O)O)O
InChI InChI=1S/C28H44N4O8/c1-15(2)21-19(25(32-31-21)40-26-24(36)23(35)22(34)20(13-33)39-26)12-17-7-8-18(11-16(17)3)38-10-6-9-30-14-28(4,5)27(29)37/h7-8,11,15,20,22-24,26,30,33-36H,6,9-10,12-14H2,1-5H3,(H2,29,37)(H,31,32)/t20-,22-,23+,24-,26+/m1/s1
InChI Key LREHMKLEOJAVMQ-TXKDOCKMSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

References
1. Fukudo S, Kaku K. (2019)
Effect of Mizagliflozin on Postprandial Plasma Glucose in Patients With Functional Constipation.
J Neurogastroenterol Motil, 25 (2): 332-333. [PMID:30982244]
2. Fukudo S, Kaku K. (2019)
Future Possibility of Mizagliflozin on Functional Constipation and/or Irritable Bowel Syndrome With Constipation.
Gastroenterology, 157 (3): 898-899. [PMID:31228444]
3. Inoue T, Takemura M, Fushimi N, Fujimori Y, Onozato T, Kurooka T, Asari T, Takeda H, Kobayashi M, Nishibe H et al.. (2017)
Mizagliflozin, a novel selective SGLT1 inhibitor, exhibits potential in the amelioration of chronic constipation.
Eur J Pharmacol, 806: 25-31. [PMID:28410751]
4. Luthra P, Camilleri M, Burr NE, Quigley EMM, Black CJ, Ford AC. (2019)
Efficacy of drugs in chronic idiopathic constipation: a systematic review and network meta-analysis.
Lancet Gastroenterol Hepatol, 4 (11): 831-844. [PMID:31474542]
5. Spiller R. (2018)
Inhibiting glucose absorption to treat constipation.
Lancet Gastroenterol Hepatol, 3 (9): 588-589. [PMID:30056027]
6. (2018)
Correction to Lancet Gastroenterol Hepatol 2018; 3: 603-13.
Lancet Gastroenterol Hepatol, 3 (9): e4. [PMID:30102185]